- Ocugen shares are highly volatile and retail follows closely.
- OCGN shares have spiked on the back of covid vaccine news
- OCGN wants to bring a covid vaccine to the US market.
Ocugen is a medical company that was focused on eye diseases but quickly changed focus once the pandemic hit. Ocugen now has one of its strongest business opportunities in the development of a covid-19 vaccine. OCGN has partnered with India's Bharat Biotech to bring its COVAXIN COVID-19 vaccine to the US market.
OCGN stock price
Ocugen shares have been highly volatile the past number of months. Operating in the biotech medical sector can be volatile anyway due to regulatory and trial data, but Ocugen has seen increased volatility as a result of its pivot toward covid vaccine development.
OCGN shares traded around $0.30 in December but spiked to nearly $20 by February. The catalyst was OCGN partnering with Bharat Biotech. Bharat is an Indian vaccine company that is working on bringing its COVAXIN COVID-19 vaccine to market. Ocugen will look after bringing COVAXIN to the US market, including regulatory approval and distribution.
On February 8, OCGN shares spiked on the news of a share placing. Normally, share placings are done at a discount to the market, but this was done at a premium. Retail traders jumped on the news and sent OCGN shares soaring.
Since then, it has largely moved sideways to lower as OCGN filled the gap caused by the initial spike and broke several key support levels along the way.
OCGN jumped again on April 22 as positive trial data for the COVAXIN drug was released to the market. OCGN shares failed to take out previous highs set back in February but did still manage to register an impressive 42% gain. Further spikes were seen on May 3 as Ocugen announced that COVAXIN proves effective against the main variants of the covid virus.
Ocugen is to release results for the first quarter 2021 on Friday, May 7. Earnings per share are expected to be $0.50.
OCGN technical levels
The failure to break new highs recently is in itself a bearish argument. Investors and traders now have more information following trial results and positive results in relation to COVAXIN's effectiveness against covid variants. With this new information, the risk profile of the investment has actually lowered since the highs seen on February 8. Remember, the move on February 8 was sparked by Ocugen announcing a premium share placing. At this time not enough was known about the trial results of COVAXIN or its viability against covid and covid variants. Now that they have that information or more information at least, the risk of success or failure of COVAXIN has tilted more toward success, but OCGN shares have not recaptured old highs. This tells us that the earlier move in February was too much pure speculation and froth or we are missing something.
For now, OCGN remains in bullish formation with a series of higher lows and sits comfortably above the main moving averages. Support is key at $11.70 and then $9.87. These levels are the 9 and 21-day moving averages respectively. A break below $9.87 would then see OCGN look to reestablish itself in the consolidation area below $7.
Resistance is from the February high of $18.77. Results will be important but more important will be news around the commercial and regulatory viability of COVAXIN.
At the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Errors and omissions excepted.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD corrects toward 0.6850, awaits US PCE Price Index
AUD/USD is falling back toward 0.6850 in Friday's Asian trading, reversing from near 19-month peak. A tepid US Dollar bounce drags the pair lower but the downside appears called by the latest Chinese stimulus measures, which boost risk sentiment ahead of US PCE data.
USD/JPY pares gains below 145.50 after Tokyo CPI inflation data
USD/JPY is paring back gains to trade below 145.50 in the Asian session on Friday, as Tokyo CPI inflation data keep hopes of BoJ rate hikes alive. However, intensifying risk flows on China's policy optimism support the pair's renewed upside. The focus shifts to the US PCE inflation data.
Gold price consolidates below record high as traders await US PCE Price Index
Gold price climbed to a fresh all-time peak on Thursday amid dovish Fed expectations. The USD languished near the YTD low and shrugged off Thursday’s upbeat US data. The upbeat market mood caps the XAU/USD ahead of the key US PCE Price Index.
Avalanche rallies following launch of incentive program for developers
Avalanche announced the launch of Retro9000 on Thursday as part of its larger Avalanche9000 upgrade. Retro9000 is a program designed to support developers with up to $40 million in grants for building on the Avalanche testnet.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.